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Herein, we investigated the role of VEGF signaling in the earliest events in vasculogenesis and found that it exerts critical effects shortly
after mesodermal cells form by gastrulation. We showed that VEGF treatment of embryos caused an increase in the population of newly
gastrulated mesodermal (NGM) cells that express the transcription factor TAL1. This increase in TAL1-positive cells was attributed to VEGF
induction of VEGF receptor-2 (Flk1)-positive NGM cells that would normally not have been induced due to the limited availability of VEGF
in the NGM. Evidence that VEGF-mediated induction of NGM cells is relevant to the endothelial lineage is the finding that induced TAL1-
positive cells in the NGM formed ectopic structures whose cells exhibited characteristics of endothelial cells, including the ability to integrate
into the vascular network and express the QH1 antigen. Finally, we showed that VEGF-induced TAL1 expression in the NGM which resulted
in the formation of ectopic structures was mediated by Flk1 but not Flt1 signaling. In summary, we have established that VEGF signaling is
critical to allocation of NGM to the endothelial lineage.
D 2004 Elsevier Inc. All rights reserved.
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Vasculogenesis, the de novo formation of blood vessels,
has several key components beginning with lineage
formation from undifferentiated mesodermal cells followed
by successive morphogenic events that culminate in the
formation of a vascular epithelium (i.e., a blood vessel).
Although vascular endothelial growth factor (VEGF) has
been linked to all aspects of the morphogenic events
associated with blood vessel formation, its precise role in
endothelial lineage formation is uncertain. Genetic ablation
of either VEGF or VEGF receptor-2 (VEGFR-2/Flk1) in
mice leads to defective endothelial and hematopoietic
lineage formation (Carmeliet et al., 1996; Ferrara et al.,0012-1606/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: drakec@musc.edu (C.J. Drake).1996). These defects highlight a lineage interrelationship
that has long been a subject of investigation (Choi, 2002; de
Bruijn et al., 2002; Jaffredo et al., 1998, 2000; Jordan, 1916;
Munoz-Chapuli et al., 1999; Sabin, 1920). Indeed, endo-
thelial cells and hematopoietic cells share expression of
numerous proteins including CD31/PECAM (Newman and
Albelda, 1992), CD34 (Fina et al., 1990), Tie1 and 2
(Dumont et al., 1995), and the bHLH transcription factor
TAL1 (Kallianpur et al., 1994).
Along with Flk1, TAL1 is one of the earliest described
markers of the endothelial lineage (Drake et al., 1997;
Kallianpur et al., 1994). This and other findings implicate
TAL1 in the regulation of the endothelial lineage. For
example, ectopic expression of TAL1 in zebrafish and mice
promotes the generation of the endothelial lineage (Gering
et al., 1998, 2003). Additionally, a genetic mutation (cloche)
that leads to Flk1 deficiency and a consequential failure in
vasculogenesis could be rescued by forced expression of
TAL1 (Liao et al., 1997, 1998). Experiments described
herein further evaluated the relationship between VEGF279 (2005) 169–178
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endothelial lineage.Materials and methods
Quail microinjection, microsurgery, and ex ovo culture
Methods for microinjection, microsurgery, and ex ovo
culture have been previously described (Drake and Little,
1995, Drake et al., 1992, 1997). Briefly, Japanese quail
(Coturnix coturnix japonica) embryos at the 4–6 somite
stage were removed from the yolk using paper rings, rinsed
in phosphate-buffered saline (PBS) and placed ventral side
up in 35-mm Petri dishes containing a bed of 5% agar.
Approximately 25 nl of recombinant human vascular
endothelial growth factor 165 (rhVEGF165) (R&D Systems,
Minneapolis, MN) at 0.5 mg/ml was microinjected into the
interstitial space between the endoderm and splanchnic
mesoderm using glass micropipettes. Stage-matched control
embryos were cultured alongside experimental, micro-
injected embryos. To allow the contralateral side of an
embryo to act as a control, microsurgery was performed on
the VEGF-injected embryos. After injection on one side, as
described above, embryos were washed in PBS to eliminate
residual VEGF and then bisected along the midline. All
embryos were cultured for either 7 or 14 h (378C, 5% CO2)
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco
BRL/Life Technologies, Baltimore, MD) containing 10%
chick serum (Gibco BRL/Life Technologies), 1% Penn/
Strep, and 1% Glutamine (Gibco BRL/Life Technologies).
Explant culture
In vitro studies were conducted to discriminate between
induction and migration as a mechanism for the increased
number of TAL1-positive cells observed as a response to
VEGF. Using a double-edged, carbon steel blade (Electron
Microscopy Sciences, Ft. Washington, PA), small pieces of
tissue from either the region containing NGM or more cranial
regions lateral to the second somite were isolated. Tissue
from the NGM region lacking endothelial cells was dissected
so as to avoid any contaminating lateral tissues that contain
blood vessels. Isolated tissues were cultured in the presence
or absence of VEGF (1 Ag/ml) for 7 h (378C, 5% CO2) in
DMEM (Gibco BRL/Life Technologies) containing 10%
chick serum (Gibco BRL/Life Technologies), 1% Penn Strep,
and 1% Glutamine (Gibco BRL/Life Technologies).
Fixation, immunolabeling, preparation of sections, and
their immunolabeling
Fixation, immunolabeling, laser scanning confocal
microscopy (LSCM), and image processing of early stage
avian embryos have been described previously (Drake et al.,
1992, 1997). Following the culture period, embryos orcultured explants were rinsed in PBS and fixed in 4%
paraformaldehyde (45 min, 258C; Sigma, St. Louis, MO).
After washing in PBS plus 0.01% azide (PBSA), the
vitelline membrane was removed from embryos and both
embryos and explants were permeabilized in absolute
methanol (1 h, 208C), rehydrated through a series of
ethanol/water solutions (100%, 80%, 50%, 30%) and then
blocked in 3% bovine serum albumin/DPBSA (8–12 h,
48C). The embryos were washed and immunolabeled using
QH1 hybridoma supernatant and rabbit anti-recombinant
TAL1 antibody. TAL1 antibody was obtained from Stephen
J. Brandt (Vanderbilt University and VA Medical Center,
Nashville, TN). The QH1 hybridoma developed by F.
Dieterlen was obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the
NICHD and maintained by the University of Iowa, Depart-
ment of Biological Sciences, Iowa City, IA 52242. After
three 30-min washes in PBSA, embryos and explants were
immunolabeled with appropriate fluorochrome-conjugated
secondary antibodies (Jackson ImmunoResearch Labs, Inc.,
West Grove, PA). Embryos were then mounted on glass
slides under no. 0 cover slips (Fisher Scientific, Sewanee,
GA) using an anti-photobleaching mounting medium (Giloh
and Sedat, 1982).
To evaluate the morphology of VEGF-induced QH1/
TAL1-expressing structures, quail embryos previously
treated with VEGF for 14 h and evaluated by whole-mount
immunofluorescence microscopy were further processed for
cross-sectional analysis of the structures. Briefly, embryos
were dehydrated through a series of graded ethanol: water
solutions (30%, 50%, 80%, and 100%) for 30 min each. The
embryos were infiltrated with 100% Histo-Clear (National
Diagnostics, Atlanta, GA) for 2 h and then processed
through a graded series of Histo-Clear/paraffin solutions
(3:1, 1:1, 1:3) for 15 min each. The embryos were finally
infiltrated with 100% paraffin two times for 1 h each,
embedded in paraffin, cut into 3-Am transverse and saggital
sections using a Spencer microtome, floated onto glass
slides, and allowed to dry over low heat. Sections were then
cleared using Histo-Clear (3  10 mins), rehydrated with a
graded series of ethanol: water solutions (100% and 95%)
and transferred into PBSA. Sections were mounted under
no. 0 cover slips using an anti-photobleaching mounting
medium (Giloh and Sedat, 1982).
Microscopy and imaging
Whole-mounted embryos or sections of embryos were
imaged using either a Bio-Rad MRC-1024 laser scanning
confocal microscope (BioRad, Microscopy Division, Cam-
bridge, MA) or a Leica DMR light microscope equipped
with epifluorescence and differential interference contrast
(DIC) optics (Vashaw Scientific, Raleigh, NC). Images were
processed using Image J 1.31v (National Institutes of
Health) and Adoben Photoshopn 7.0 software (Adobe
Systems, San Jose, CA).
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Receptor selective VEGF ligands were generously pro-
vided by Dr. Napoleone Ferrara at Genentech Inc., San
Francisco, CA. The Flk1-selective VEGF ligand was
generated by three substitutions (Asp-63 to Ser, Gly-65 to
Met, and Leu-66 to Arg) in human VEGF-A and is referred to
as KDR-sel (Flk1-sel). The Flt1-selective VEGF ligand was
generated by four alanine substitutions (positions 43, 46, 79,
and 83) in human VEGF-A and is referred to as Flt-sel. The
receptor-selective VEGF ligand Flk1-sel binds to Flk1 with
wildtype affinity but has approximately a 2000-fold reduced
affinity for Flt1, while Flt-sel binds Flt1 with wildtype
affinity but has at least a 470-fold reduced affinity for Flk1 (Li
et al., 2000). Quail embryos were microinjected with 0.3 mg/
ml VEGF, Flk1-sel, or Flt-sel and evaluated for TAL1 and
QH1 antigen expression at 7 and 14 h post-injection.
RT-PCR (QPCR) analysis of newly gastrulated mesoderm
and lateral mesoderm
To evaluate the effects of VEGF treatment on TAL1 and
Flk1 mRNA expression, 4–6 somite quail embryos were
microinjected with 0.3 mg/ml VEGF and cultured for 7 h
(378C, 5% CO2) as described above. Following culture,
regions of NGM were dissected away as described above.
The mRNA from these explants was extracted using
RNAStat60 (Tel-Test, Friendswood, TX), DNase treated
with TURBO DNAfree (Ambion Inc, Austin, TX), and
reverse transcribed (2 Ag each) with SuperScriptk First-
Strand Synthesis System (Invitrogen, Carlsbad, CA). QPCR
was then performed on cDNA using the following primers:
GAPDH, sense primer 5V-AGA ACA TCA TCC CAG CGT
CCA CT-3V and antisense primer 5V-CGG CAG GTC AGG
TCA ACA ACA GA-3V; Quek1/Flk1, sense primer 5V-ACA
AGTATG GCT CAA CGC AGA-3V and antisense primer 5V-
GAT TGG CTC CCA GGC GAA CTT T-3V and TAL1, sense
primer 5V-CCA TCG GCA GCG GGT TCT TC-3V and
antisense primer 5V-GCG GCG GAC CAC CTT CGT GT-3V.
Amplification of cDNAs was performed using an iCycler iQ
Real Time Peltier thermocycler (Bio-Rad Laboratories, Inc,
Headquarters, Hercules, CA) for 55 cycles with denatura-
tion at 958C for 30 s, annealing at 65.78C for 30 s, and
extension at 728C for 30 s. Fluorescence was monitored
during the 72.08C extension step. A melting curve was
performed with continuous fluorescence measurement
between 548C and 958C with a transition rate of 0.58C/s.
The external standards were amplified simultaneously and
were 10-fold serial dilutions of RT-PCR products. Results
were analyzed with the iCycler iQ Real Time Detection
software v 3.0 (Bio-Rad Laboratories, Inc, Headquarters,
Hercules, CA). Absence of primer-dimer and nonspecific
product accumulation was checked by melting curve
analysis and confirmed by agarose gel electrophoresis.
Final amounts of reagents in the reaction were 1 Al of
cDNA template diluted 1:5, 0.4 mM of each primer, and12.5 Al of iQkSYBR Green Supermix (Bio-Rad Labo-
ratories, Inc, Headquarters, Hercules, CA) consisting of
100 mM KCl, 40 mM Tris–HCl, pH 8.4, 0.4 mM of each
dNTP (dATP, dCTP, dGTP, and dTTP), iTaq DNA
polymerase, 50 units/ml, 6 mM MgCl2, SYBR Green I,
20 nM fluoresein, and stabilizers in a final volume of 25
Al. Data were expressed as threshold cycle values, Ct,
which is the point when the logarithmic PCR plots cross a
threshold line. The Ct values were in turn used to calculate
the DCt (DCt = Ct of the target gene minus Ct of control
gene GAPDH) values for all of the unknown samples.
Change in mRNA levels was calculated using the equation
2(DCt of experimental group  DCt control group) (Chan et al.,
2004). Statistical analysis of QPCR results was carried out
by first averaging DCt values for each sample (pooled
NGM regions from VEGF-injected embryos). Average
DCt values were then used to calculate the fold change in
either TAL1 or Flk1 mRNA expression. No significant
difference was observed between the threshold cycle of
the internal standard gene, GAPDH. Standard deviation of
the fold changes of target genes was calculated using
individual fold change values for TAL1 and Quek1/Flk1
and Student’s t test was used to compare fold change
differences between genes of interest.Results
Elevated VEGF levels cause an increase in the
TAL1-positive population of newly gastrulated
mesodermal cells
To assess the influence of VEGF/VEGF-receptor signal-
ing on regulation of TAL1 expression, 4–6 somite stage
quail embryos were microinjected with rhVEGFA165 and
then cultured for 7 h at which time they had reached 9–11
somites. Since our previous studies had shown that injected
VEGF could diffuse across the midline (Drake and Little,
1995), we employed a microsurgical protocol that allowed
the side of the embryo contralateral to the site of VEGF
injection to serve as negative control (Fig. 1A). As shown
in Fig. 1B (asterisk), VEGF induced a dramatic increase in
TAL1 staining in a region caudal and lateral to Henson’s
Node, a region populated by newly gastrulated mesoderm
(NGM). In contrast, the contralateral side of the embryo
showed little TAL1-positive labeling in the NGM region
(Fig. 1C, asterisk). The discrete boundary between TAL1-
positive NGM and adjacent TAL1-negative mesoderm
(Fig. 1B, arrowheads) on the injected side and the lack
of TAL1-positive mesoderm located in more cranial
regions of the embryo suggested that the response to
VEGF was not ubiquitous to mesoderm but was confined
solely to the NGM region. Evidence that VEGF was
having an effect outside of the region of NGM was the
observation that blood vessels on the injected side of the
embryo underwent vascular hyperfusion, revealed using
Fig. 1. VEGF causes an increase in the TAL1-positive population of newly gastrulated mesodermal cells. Shown are images of a 9-somite quail embryo that
was VEGF-injected on the left side at 4-somites with rhVEGF165 (0.5 mg/ml). Immediately after injection, the embryo was split along the midline and cultured
for 7 h. At the end of the culture period, the embryo was fixed and immunolabeled with and antibodies to TAL1 (green) and the quail endothelial cell marker,
QH1 (red). Panel A shows a brightfield image of the embryo. Boxed areas (band C) correspond to higher magnification confocal images shown in panels B and
C. Panel B shows caudal region of the VEGF-injected side of the embryo. Asterisk in B indicates a region with increased TAL1 expression. Boxed area in B
shows hyperfused vessels. Arrowheads indicate the boundary between TAL1-positive NGM and adjacent TAL1-negative mesoderm. Panel C shows the
contralateral side of the same embryo. Panels D and E are higher magnification views of the areas marked by asterisks in panels B and C, respectively. Scale
bars equal 500 Am (A), 100 Am (B and C), and 50 Am (D and E). M, medial; L, lateral.
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Figs. 1B and C, boxed areas).
When higher magnification imaging was performed on
VEGF-injected embryos, it was evident that the population
of TAL1-positive cells in the NGM increased on the
injected side as compared to the contralateral side. By
contrast to the densely packed TAL1-positive cells in the
NGM on the VEGF injected side, TAL1-positive cells on
the contralateral side were few in number and widely
separated (compare Figs. 1D and E). On both sides of the
embryo, TAL1 immunolabeling in NGM cells was confined
to the nucleus, consistent with TAL1 being a transcription
factor (Fig. 1E). Additionally, it was observed that the
distribution of TAL1-positive cells in the NGM was graded
medial-laterally with the lowest density of TAL1-positive
cells nearest the axis and the highest density of TAL1-
positive cells furthest from the axis (Figs. 1E and D).
Double labeling of embryos with antibodies to TAL1 and
the nuclear stain, propidium iodide (PI), revealed that
TAL1-positive cells observed in the NGM of the VEGF-injected side are a subpopulation of NGMCs intermingled
with TAL1-negative NGMCs (Fig. 2).
VEGF treatment increases TAL1 mRNA expression in NGM
To determine whether augmented levels of VEGF-
mediated TAL1 immunolabeling in the NGM correlated
with alterations in TAL1 mRNA levels, QPCR was
performed on RNA isolated from NGM tissue in VEGF-
injected embryos. As shown in Fig. 3, VEGF treatment led
to a significant increase (~2-fold) in TAL1 transcripts. By
contrast, VEGF treatment did not significantly alter Flk1
mRNA levels in the NGM (Fig. 3).
VEGF induces TAL1 expression in the NGM but does not
promote immigration of TAL-positive cells from outside
the NGM
Having established that VEGF treatment resulted in an
increase in the TAL1-positive population of NGM cells, we
Fig. 4. VEGF induces TAL1 in a subpopulation of newly gastrulated
mesodermal cells. Shown in Panels A and B are explants derived from
regions cranial and lateral to the NGM that were cultured in the presence (A)
or absence (B) of VEGF. In Panels C and D, explants derived fromwithin the
region of theNGMwere cultured in the presence (C) or absence (D) of VEGF.
Shown are confocal microscopy images of explants after immunolabeling
with QH1 (red) and TAL1 (green) antibodies. The hyperfusion response
Fig. 2. The TAL1-positive cells in VEGF-injected embryos represent a
subpopulation of the newly gastrulated mesodermal cells. Shown is the
caudal portion of a 9-somite quail embryo that was injected on the right side
at 4-somites with rhVEGF165 (0.5 mg/ml) and stained with anti-TAL1
(green) and the DNA intercalating dye, propidium iodide (red). TAL1
immunolabeling is evident within the nuclei of cells within the NGM
region. Such cells were intermingled with TAL1-negative/propidium iodide
stained NGMCs. Scale bar equals 100 Am.
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within NGM cells. To test this hypothesis, small pieces of
NGM tissue (4–6 somite stage) were isolated such that each
lacked tissue from regions lateral to the NGM that contain
endothelial cells. These NGM explants were cultured in the
absence or presence of VEGF. Confocal analysis of these
NGM explant cultures labeled with antibodies to TAL1
showed that there were more TAL1-positive nuclei in the
VEGF-treated explants as compared to control explants (Fig.
4). As was observed in intact embryos injected with VEGF
(Fig. 1), there were more TAL1-positive cells on the side of
the explant that was originally most distal from the axis.
shown in Panel A is characteristic of the in vivo response to VEGF of meso-
derm from regions cranial and lateral to the NGM. Scale bars equal 50 Am.
Fig. 3. VEGF treatment increases TAL1 mRNA expression in NGM. QPCR
was performed on cDNA generated from total RNA isolated from NGM
tissue from VEGF-injected embryos. Plotted values are the means F the
standard deviation of 9 replicates for each gene-specific primer pair. A
Student’s t test was performed to determine whether differences between
experimental and control samples were significantly different.VEGF-mediated TAL1 expression leads to the formation of
QH1-positive mesodermal structures that integrate with
adjacent blood vessels but lack lumens
To investigate the consequences of increased numbers of
TAL1-positive cells in the NGM on vasculogenesis and/or
hematopoiesis, we evaluated embryos 14 h following VEGF
injection. Confocal analysis using QH1 immunolabeling
revealed the presence of anomalous structures in the NGM
region (Fig. 5A asterisks). The site at which these
anomalous structures formed directly corresponded with
the region of NGM where TAL1-expression had been
observed in VEGF-injected embryos following 7 h of
culture (Fig. 1B). The lateral margins of the structures were
found to integrate with the endothelial cells of blood vessels
Fig. 5. VEGF-induced TAL1 expression correlates with the formation of
structures of mesodermally derived cells that exhibit properties of
endothelial cells but do not form lumens. Depicted are confocal images
of VEGF-injected (A) and control (B) embryos that were cultured for 14 h
and subsequently immunolabeled with QH1 antibody. Asterisks in panel A
indicate ectopic structures induced by VEGF treatment in a normally
avascular regions caudal and lateral to Henson’s node (asterisks in panel B).
Arrows indicate the interconnections of the ectopic structures with blood
vessels located more laterally. Scale bar equals 500 Am.
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To determine whether the structures contained lumens,
an optical Z series of the entire structure was acquired
(composed of 23 optical sections, 5 Am thick). Analysis of
the entire z-series showed that no lumens could be found
within the structure (representative optical sections are
depicted in Fig. 6). This analysis revealed a discontinuous
dorsoventral distribution of QH1 labeling with the highest
level of immunolabeling located in the most ventral
portion of the structure, which is juxtaposed to the
endoderm (Fig. 6B). By contrast, QH1 labeling was low
or not detectable in the dorsal portion of the structure. No
difference was apparent in the density of TAL1-positive
cells or the level of TAL1 expression throughout the
structure. The fact that QH1 labeling is greatest in regions
closest to the endoderm is consistent with findings
showing that endoderm is a source of factors that promote
vasculogenic activities subsequent to lineage formation
(Vokes and Krieg, 2002).VEGF-induced QH1-positive mesodermal structures do not
display evidence of hematopoietic differentiation
We next evaluated the VEGF-induced structures in
conventional cross section of paraffin-embedded embryos.
Analysis of differential interference contrast (DIC) images
of embryo sections showed the structures consisted of
densely packed, small diameter (10.4 F 2.7 Am, n = 7)
mesodermal cells located between the endoderm and
ectoderm (Fig. 7). DIC analysis showed no evidence for
lumens in the structures. QH1 immunolabeling of these
sections showed that QH1 expression was graded, with
highest expression located proximal to the endoderm. The
lack of discernable lumens raised the possibility that the
QH1-labeled regions of the structures might contain
hematopoietic cells as are seen in blood islands. To evaluate
this possibility, we examined sections of the yolk sac
containing blood islands. DIC and epifluorescence micro-
scopy showed that yolk sac blood islands contained large
(15.2 F 2.5 Am diameter, n = 7) round cells bound by QH1-
positive endothelial cells. Furthermore, this analysis
revealed that the rounded hematopoietic cells do not express
the QH1 antigen. Based on these findings, we conclude that
the VEGF-induced structures bear no morphological sim-
ilarities to blood islands.
VEGF-induced TAL1 expression and the formation of the
ectopic structures are mediated through Flk1 but not Flt1
To discriminate between Flt1 and Flk1 as the receptor
mediating VEGF-induction of TAL1, we evaluated the
ability of the receptor-selective VEGF mutants, KDR-sel
(Flk1-sel), (Flk1-selective), and Flt-sel (Flt1-selective) to
induce TAL1 expression and to promote ectopic structure
formation in the NGM region. Analysis of staged-
matched quail embryos microinjected with Flk1-sel or
Flt-sel revealed that only Flk1-sel could induce the
formation of QH1-positive ectopic structures (Fig. 8). Al-
though Flt-sel failed to induce either the expression of
TAL1 (data not shown) or the formation of ectopic
structures, it was able to induce the hyperfusion of blood
vessels in the lateral mesoderm (i.e., increase in vessel
size (diameter) with a concomitant loss of avascular
space) (Fig. 8B).Discussion
Our findings establish that VEGF signaling (i.e.,
VEGFA165/Flk1 signaling) can act as an upstream regulator
of TAL1 protein expression in a subpopulation of NGM
cells. Further, we showed that VEGF not only promoted the
expression of TAL1 in NGM cells but led to the formation
of ectopic structures that express the QH1-immunoreactive
antigen, a marker of quail endothelial cells. Though these
ectopic structures lacked lumens, they were able to integrate
Fig. 6. Confocal imaging of VEGF-induced ectopic structures labeled with TAL1 and QH1 antibodies. Shown in Panel A is a composite image of a VEGF-
induced ectopic structure generated by collapsing 23 (5 Am) optical sections in the Z plane (z-series) onto one focal plane. Panels B–D each depict composites
of two optical Z-sections taken from the ventral, medial and dorsal aspects of the structure, respectively. Scale bar equals 50 Am.
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findings, we conclude that VEGF has the ability to drive
NGMCs toward the endothelial lineage and that TAL1
expression is an early event in endothelial lineage specifi-
cation from NGM. Furthermore, we showed that the effects
of VEGF on NGMCs are mediated by Flk1 but not Flt1
signaling. Consistent with this conclusion are findings from
others showing that NGMCs express high levels of Flk1
mRNA (Nimmagadda et al., 2004) and lack Flt1 expression
(Breier et al., 1995; Fong et al., 1996). Together, these
findings suggest that VEGF signaling in the NGM is
physiologically relevant. Indeed, under normal conditions,
we observed that that the NGM does contain isolated TAL1-
positive cells. Since exogenously administered VEGF can
dramatically increase the number of TAL1-positive cells in
the NGM, it is reasonable to speculate that TAL1-positive
cells within the normal NGM arise from controlled VEGF/
Flk1 signaling in the NGM region.
A major tenet of our work is that VEGF acts to induce
TAL1 expression in a subpopulation of NGMCs and is not
merely acting to promote immigration of TAL1-positive
cells from outside of the region of NGM. Several
observations support this view. Most importantly, we
showed that in explant culture, isolated pieces of NGMlacking endothelial cells could be induced to express TAL1
in response to VEGF treatment. This observation and the
fact that TAL1 induction in intact embryos was confined to
the NGM region argues against the possibility that VEGF
acted to promote migration of TAL1-positive cells from
outside of the NGM. It is not clear why endogenous VEGF
induces only a subpopulation of NGMCs to express TAL1.
One possibility is that only a subset of NGMCs expresses
VEGF receptors or that all NGMCs are VEGF-receptor
positive and the bioavailability of VEGF could be limiting.
Our finding that VEGF treatment can induce TAL1
expression in an increased number of NGMCs suggests
that VEGF receptor may be expressed by most if not all
NGMCs. This suggests that the bioavailability of VEGF in
the NGM region might be limiting and thus only able to
induce a subpopulation of NGMCs. Evidence that VEGF
bioavailability and/or dose are critical is evident from
several findings. For example, mice heterozygous for
targeted deletion of VEGF-A exhibited impaired blood
island and blood vessel formation that resulted in lethality at
E11.5 dpc (Carmeliet et al., 1996; Ferrara et al., 1996).
Similarly, a mutation in the VEGF-A gene, Vegflo, results in
a hypomorphic phenotype that includes a reduction in
dmultipotent mesenchymal cellsT (Duan et al., 2003) which
Fig. 7. QH1 immunolabeling discriminates between cells of VEGF-induced ectopic structures and hematopoietic cells of blood islands. Shown in Panels A and
B are DIC (A) and epifluorescence (B, QH1-labeled) microscopic images of a 3-Am transverse paraffin section of a VEGF-induced ectopic structure. Shown in
Panels C and D are DIC (C) and epifluorescence (D, QH1-labeled) microscopic images of a transverse paraffin section of a yolk sac containing blood islands
(boxed area). Endo, endoderm; Ecto, ectoderm. Scale bar equals 50 Am.
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positive NGM.
The observation that VEGF can induce the expression of
TAL1 in the NGM brings into question the significance of
TAL1 to the generation of lineages derived from NGM. The
observation that the ectopic expression of TAL1 in zebrafish
promotes generation of the hematopoietic and endothelialFig. 8. An Flk-specific VEGF mutant induces ectopic structure formation wherea
injected (A), Flt-sel-injected (B), and control (C) embryos that were cultured for
antibodies. Brackets in each panel indicated the avascular space between the
approximately 160, 350, and 370 Am for Panels A–C, respectively. Scale bars eqlineages at the expense of other mesodermal cell fates (i.e.,
somites) (Gering et al., 1998, 2003) suggests a critical role
for TAL1 in hematopoietic and endothelial lineage for-
mation. Indeed, gene deletion studies confirm the critical
role of TAL1 in the hematopoietic lineage but do not
support such a role in the endothelial lineage (Robb et al.,
1995; Shivdasani et al., 1995). In contrast, findings thats an Flt-specific mutant does not. Depicted are confocal images of Flk-sel-
14 h and subsequently immunolabeled with QH1 (red) and TAL1 (green)
axis and lateral blood vessels or ectopic structures. Bracket lengths are
ual 100 Am.
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lial cells engaged in de novo blood vessel formation (Drake
et al., 1997, 2000; Minko et al., 2003) suggest a role for
TAL1 in the endothelial lineage, or at the very least is a
reflection of the cells from which they were derived. In this
regard, the hemangioblast has been proposed to represent
the common progenitor of both the endothelial and
hematopoietic lineages (Choi, 2002; Munoz-Chapuli et al.,
1999; Sabin, 1920). Alternatively, it has been proposed that
endothelial cells are the source of hematopoietic cells (de
Bruijn et al., 2002; Jaffredo et al., 1998, 2000). Such cells
have been referred to as hemogenic (Jaffredo et al., 2000;
Jordan, 1916; Nishikawa et al., 1998).
Administration of VEGF not only led to an increase in
the number of TAL1-positive cells in the region immedi-
ately lateral to Henson’s node, but it also led to the
formation of a QH1-positive structure in this region.
Although this abnormal structure expressed the endothelial
marker QH1 antigen and integrated with the more lateral
vascular networks, the structure lacked a lumen. This fact
precludes us from characterizing the structures as blood
vessels. We speculate that the extremely high density of
TAL1-positive cells formed in response to VEGF admin-
istration is incompatible with lumen formation which
normally occurs in isolated clusters of 3–10 cells (Drake
and Jacobson, 1988; Drake et al., 1997). Additionally, there
was no immunohistological evidence that the structures
contained hematopoietic cells. In fact, cells within the
structure expressed QH1 antigen, an endothelial cell marker
not expressed in hematopoietic cells of the blood island.
The findings presented herein led us to propose a
model for VEGF/Flk1 signaling in NGMCs that accounts
for the formation of the endothelial lineage. The model is
as follows: subsequent to gastrulation, Flk1+/Flt1
NGMCs move laterally away from the axis and are
exposed to VEGF. Limited levels of VEGF in the NGM
act to induce TAL1 expression in a subpopulation of these
NGMCs, a process that is repeated as additional cells
gastrulate and move laterally. With time, these TAL1-
positive cells (angioblasts) give rise to endothelial cells.
Based on our observations, the window of time in which
NGMCs can become induced by VEGF to express TAL1
is restricted to a brief period immediately following
gastrulation when mesodermal cell commitment is occur-
ring. Evidence for a limited spatio-temporal window for
NGMC specification by VEGF comes from the finding
that VEGF administration did not cause TAL1 induction in
mesoderm in regions of the embryo cranio-lateral to
Hensen’s node (i.e., in mesoderm lateral to somites as
opposed to that in the NGM region) that had gastrulated
earlier. By contrast, NGMCs that are not induced by
VEGF (i.e., NGMCs that do not up-regulate TAL1) give
rise to other cell lineages (i.e., cardiac mesoderm, somitic
mesoderm). By extension of the hemogenic endothelium
model (Jaffredo et al., 2000; Jordan, 1916; Nishikawa et
al., 1998), our model indicates that TAL1-positive cellsinduced in the region of NGM represent endothelial
progenitors (angioblasts) that give rise to TAL1-positive
endothelial cells (hemogenic) which can in turn give rise
to TAL1-positive hematopoietic cells (i.e., in blood
islands). The hemogenic potential of TAL1-positive
endothelial cells is not always manifested since most
blood vessels can form without associated hematopoiesis.Acknowledgments
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